Related Experiment Video

Updated: Aug 7, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

[Reversal of multi-drug resistance in ovarian cancer cell by RNA interference]

Jiang-yan Lou1, Zhi-lan Peng, Ying Zheng

  • 1Department of Obsterics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, China.

Zhonghua Fu Chan Ke Za Zhi
|July 13, 2006
PubMed
Abstract

Insights

Small interference RNA (siRNA) effectively inhibits multidrug resistance gene 1 (MDR1) mRNA and P-glycoprotein (P-gp) expression in ovarian cancer cells. This approach reverses resistance to certain chemotherapeutic agents, offering potential for improved treatment outcomes.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Ovarian cancer often develops resistance to chemotherapy.
  • Multidrug resistance (MDR) is frequently mediated by the MDR1 gene and its protein product, P-glycoprotein (P-gp).
  • Targeting MDR1 and P-gp offers a strategy to overcome chemoresistance.

Purpose of the Study:

  • To evaluate the efficacy of siRNA in inhibiting MDR1 mRNA and P-gp expression in ovarian cancer cells.
  • To assess the ability of siRNA to reverse chemoresistance in MDR1-overexpressing ovarian cancer cells.
  • To investigate the impact of siRNA on drug sensitivity to various chemotherapeutic agents.

Main Methods:

  • siRNA synthesis and liposomal transfection into the OVCAR8/TR human ovarian cancer cell line.
  • Quantification of MDR1 mRNA levels using real-time RT-PCR post-transfection.
  • Detection of P-gp expression via flow cytometry and assessment of drug sensitivity using ATP-bioluminescence assays.

Main Results:

  • siRNA demonstrated significant suppression of MDR1 mRNA and P-gp expression, with maximal effects observed at 48 and 72 hours, respectively.
  • Ovarian cancer cells showed restored sensitivity to paclitaxel and doxorubicin after siRNA treatment.
  • Resistance to cisplatin remained largely unaffected by the siRNA intervention.

Conclusions:

  • RNA interference (RNAi) is feasible in ovarian cancer cells.
  • siRNA effectively downregulates MDR1 mRNA and P-gp expression.
  • siRNA can reverse P-gp-mediated chemoresistance to specific agents, highlighting its therapeutic potential.

More Related Videos

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...